GNU social JP
  • FAQ
  • Login
GNU social JPは日本のGNU socialサーバーです。
Usage/ToS/admin/test/Pleroma FE
  • Public

    • Public
    • Network
    • Groups
    • Featured
    • Popular
    • People

Embed Notice

HTML Code

Corresponding Notice

  1. Embed this notice
    agaperealm (agaperealm@poa.st)'s status on Tuesday, 03-Dec-2024 07:13:31 JSTagaperealmagaperealm
    in reply to
    • DeezMistaReez :verified:
    • BowserNoodle ☦️
    • Ovpod
    • Jeff "never listens to women" Cliff, B.Sc. 😷 🇮🇷🇱🇧🇨🇦🧯🏴‍☠️🦝🐙 🐧
    @jeffcliff @DeezMistaReez @BowsacNoodle @Ovpod "the vaccine PREVENTS more myocarditis and blood clotting than it causes.
    heart.bmj.com/content/110/9/635";

    I was going to stay out of this. Congrats. You got be back in. I don't suppose you've done a click on the BMJ Group's About Us page. Or, maybe you have and you're aligned with the sky is falling climate emergency crowd. Either way, this organization has a far Left leaning agenda and I wouldn't trust any research sanctioned, funded, promoted or produced by them. Remember 99% of scientists agree with the opinion of those funding them.

    It is hard to find people these days who aren't aware of the COVID-19 "vaccination" myocarditis pericarditis connection. Even the completely compromised CDC has had to publish the connection. Considering the CDC's initial position on the vaxes was that they're completely safe and almost 100% effective at preventing transmission or contraction of COVID-19, this is a surprising admission to me.

    cdc.gov/vaccine-safety/vaccines/covid-19.html#cdc_generic_section_6-a-closer-look-at-the-safety-data

    We've all been waiting for decades for a vaccine to cure the common cold. The flu vaccine 20% to 30% effective after decades of use. Enter COVID-19. Within 9 months 4 different companies have a vax based on a new, untested mRNA tech. LOFL. Nothing to be suspicious of there. They initially tell us, "Almost 100% effective at preventing contraction and transmission" but within 6 months they've gradually reduced that to 40% effective. Ah, but we have a booster we can sell you to solve that problem. LOL. Again, nothing to be suspicious of here. And the Pfizer clinical data? You don't need to see that for...70 years. Fortunately, a judge prevented Pfizer from hiding the data. And, what did we find in their clinical results? 9 full pages of contraindications in what we were told was a perfectly safe, "experimental vaccine" that, by the way, the manufacturer's could not be held liable for people who suffered contraindications from their product. The best part? They don't have to prove efficacy and they couldn't if they even wanted to. "All of these people would have dies if they hadn't taken our experimental drug." "Well, how do you know that?" "We just know." Got it.

    Candidly, I have to hand it to big pharma on this one. They pulled of the most successful financial scam in corporate history. They're scum, but you have to admire their ability to execute on a grandiose plan.
    In conversationTuesday, 03-Dec-2024 07:13:31 JST from poa.stpermalink

    Attachments

    1. Domain not in remote thumbnail source whitelist: heart.bmj.com
      The role of COVID-19 vaccines in preventing post-COVID-19 thromboembolic and cardiovascular complications
      Objective To study the association between COVID-19 vaccination and the risk of post-COVID-19 cardiac and thromboembolic complications. Methods We conducted a staggered cohort study based on national vaccination campaigns using electronic health records from the UK, Spain and Estonia. Vaccine rollout was grouped into four stages with predefined enrolment periods. Each stage included all individuals eligible for vaccination, with no previous SARS-CoV-2 infection or COVID-19 vaccine at the start date. Vaccination status was used as a time-varying exposure. Outcomes included heart failure (HF), venous thromboembolism (VTE) and arterial thrombosis/thromboembolism (ATE) recorded in four time windows after SARS-CoV-2 infection: 0–30, 31–90, 91–180 and 181–365 days. Propensity score overlap weighting and empirical calibration were used to minimise observed and unobserved confounding, respectively. Fine-Gray models estimated subdistribution hazard ratios (sHR). Random effect meta-analyses were conducted across staggered cohorts and databases. Results The study included 10.17 million vaccinated and 10.39 million unvaccinated people. Vaccination was associated with reduced risks of acute (30-day) and post-acute COVID-19 VTE, ATE and HF: for example, meta-analytic sHR of 0.22 (95% CI 0.17 to 0.29), 0.53 (0.44 to 0.63) and 0.45 (0.38 to 0.53), respectively, for 0–30 days after SARS-CoV-2 infection, while in the 91–180 days sHR were 0.53 (0.40 to 0.70), 0.72 (0.58 to 0.88) and 0.61 (0.51 to 0.73), respectively. Conclusions COVID-19 vaccination reduced the risk of post-COVID-19 cardiac and thromboembolic outcomes. These effects were more pronounced for acute COVID-19 outcomes, consistent with known reductions in disease severity following breakthrough versus unvaccinated SARS-CoV-2 infection. Data may be obtained from a third party and are not publicly available. CPRD: CPRD data were obtained under the CPRD multi-study license held by the University of Oxford after Research Data Governance (RDG) approval. Direct data sharing is not allowed. SIDIAP: In accordance with current European and national law, the data used in this study is only available for the researchers participating in this study. Thus, we are not allowed to distribute or make publicly available the data to other parties. However, researchers from public institutions can request data from SIDIAP if they comply with certain requirements. Further information is available online () or by contacting SIDIAP (sidiap@idiapjgol.org). CORIVA: CORIVA data were obtained under the approval of Research Ethics Committee of the University of Tartu and the patient level data sharing is not allowed. All analyses in this study were conducted in a federated manner, where analytical code and aggregated (anonymised) results were shared, but no patient-level data was transferred across the collaborating institutions.
    2. No result found on File_thumbnail lookup.
      Coronavirus Disease 2019 (COVID-19) Vaccine Safety
      from CDC
      Learn safety information about the COVID-19 vaccine
  • Help
  • About
  • FAQ
  • TOS
  • Privacy
  • Source
  • Version
  • Contact

GNU social JP is a social network, courtesy of GNU social JP管理人. It runs on GNU social, version 2.0.2-dev, available under the GNU Affero General Public License.

Creative Commons Attribution 3.0 All GNU social JP content and data are available under the Creative Commons Attribution 3.0 license.